A retrospective cohort study to determine clinical benefits of combination therapy nivolumab plus ipilimumab in patients advanced malignancy
Latest Information Update: 29 Jul 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jul 2021 New trial record
- 08 Jun 2021 Primary endpoint has been met (Overall survival (OS)) , according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology